Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ROSEVILLE, Minn.--(BUSINESS WIRE)--Rebiotix Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of RBX2660 (microbiota suspension), intended for the treatment of recurrent Clostridium difficile infection (CDI). The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs or biologic products that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.
Help employers find you! Check out all the jobs and post your resume.
